department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Yartemlea · pharmadog

pharmadog
drugs
Yartemlea

drug

patient view →

narsoplimab

Marketedupdated 2mo ago

by $OMER OMEROS CORP

Approved

community read0 votes

all catalysts(1)

approval · 1

YARTEMLEA (NARSOPLIMAB-WUUG) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Yartemlea

generic

narsoplimab-wuug

MOA

12.1 Mechanism of Action Narsoplimab-wuug inhibits MASP-2, the effector enzyme of the lectin pathway of the complement system, blocking lectin-dependent activation of complement component 3 (C3) and C4 without affecting the classical and alternative pathways of complement. In hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), MASP-2 inhibition is thought to prevent lectin pathway-mediated cellular injury, including endothelial cell injury in small blood vessels.

indication

Coronavirus Disease 2019 (COVID-19)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$OMER

🐶 often sniffed alongside

top 3

tagApproval4 co-mentions · 1 sources
drugYARTEMLEA4 co-mentions · 1 sources
company$OMEROMEROS CORP2 co-mentions · 1 sources

Trials studying narsoplimab

phase2Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721terminatedn=31
—Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimabapproved for marketing
phase3Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrometerminatedn=6
phase2Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMArecruitingn=18